Gem-diamine 1-N-iminosugars as versatile glycomimetics: Synthesis, biological activity and therapeutic potential

Journal of Antibiotics

Volumn 62, Issue 8, 2009, Pages 407-423

  Nishimura, Yoshio ^a  

^a INSTITUTE OF MICROBIAL CHEMISTRY   (Japan)

Author keywords

1 N iminosugar; Glycosidase inhibitor; Heparanase inhibitor; Influenza virus infection; Lysosomal storage disease; Siastatin B; Tumor metastasis

Indexed keywords

CARBOHYDRATE; CARBON; GLYCOCONJUGATE; GLYCOSIDASE; GLYCOSIDASE INHIBITOR; GLYCOSYLTRANSFERASE; IMINOSUGAR; LACTONE DERIVATIVE; NITROGEN; SULFOTRANSFERASE; URONIC ACID;

ANIMAL CELL; ATOM; BIOLOGICAL ACTIVITY; CARBOHYDRATE METABOLISM; CHIRALITY; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; GLYCOSIDATION; HUMAN; HUMAN CELL; HYDROLYSIS; INFLUENZA VIRUS; LYSOSOME STORAGE DISEASE; METABOLITE; METASTASIS; MOUSE; NONHUMAN; POSITION; PRIORITY JOURNAL; PROTON TRANSPORT; REVIEW; STEREOSPECIFICITY; STREPTOMYCES; VIRUS INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; GALACTOSE; GLUCOSE; HUMANS; IMINO PYRANOSES; INDICATORS AND REAGENTS; INFLUENZA, HUMAN; LYSOSOMAL STORAGE DISEASES; MICE; NEOPLASM METASTASIS; STRUCTURE-ACTIVITY RELATIONSHIP;

ORTHOMYXOVIRIDAE; STREPTOMYCES;

EID: 70249144700     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2009.53     Document Type: Review

References (88)

1. Compain,P.&Martin,O.R.ed. Iminosugars: From Synthesis to Therapeutic Applications 1-467 (John Wiley & Sons, West Sussex, (2007)).
2. Asano, N. Naturally occurring iminosugars and related compounds: structure, distribution, and biological activity. Curr. Top. Med. Chem. 3, 471-484 (2003).
3. Inouye, S., Tsuruoka, T. & Niida, T. The structure of nojirimycin, a piperidinose sugar antibiotic. J. Antibiot. 19, 288-292 (1966).
4. Cipolla, L., La Ferla, B. & Nicotra, F. General methods for iminosugar synthesis. Curr. Top. Med. Chem. 3, 485-511 (2003).
5. Umezawa, H. et al. Purification and characterization of sialidase inhibitor, siastatin, produced by Streptomyces. J. Antibiot. 27, 963-969 (1974).
6. Nishimura, Y. Synthesis and transformation of siastatin B, a novel glycosidase inhibitor, directed toward new drugs for viral infection and tumor metastasis in Studies in Natural Products Chemistry Vol. 16 (ed. Atta-ur-Rahman), 75-121 (Elsevier, Amsterdam, (1995)).
7. Nishimura, Y., Kudo, T., Kondo, S. & Takeuchi, T. Totally synthetic analogues of siastatin B. III. Trifluoroacetamide analogues having potent inhibitory activity for tumor metastasis. J. Antibiot. 47, 101-107 (1994).
8. Nishimura, Y., Satoh, T., Kudo, T., Kondo, S. & Takeuchi, T. Synthesis and activity of 1-N-iminosugar inhibitors, siastatin B analogues for α-N-acetylgalactosaminnidase and β-N-acetylglucosaminidase. Bioorg. Med. Chem. 4, 91-96 (1996).
9. McNaught, A. D. Nomenclature of carbohydrates. Pure Appl. Chem. 68, 1919-2008 (1996)In the past many years, the incorrect terms 'azasugar' has been used by chemists refer to structures where oxygen is replaced by nitrogen. Use of the terms 'aza' should be restricted when carbon is replaced by nitrogen in the IUPAC rules of carbohydrate nomenclature. Thus, the 1-N-iminosugar described in this review is a true 1-aza-carbasugar. However, the terms '1-N-iminosugar' is expedientially used for easy discrimination from the old incorrect azasugar in this review.
10. Jespersen, T. M. et al. Isofagomine, a potent, new glycosidae inhibitor. Angew. Chem. Int. Ed. Engl. 33, 1778-1779 (1994).
11. Lillelund, V. H., Jensen, H. H., Liang, X. & Bols, M. Recent developments of transitionstate analogue glycosidase inhibitors non-natural product origin. Chem. Rev. 102, 515-553 (2002).
12. Butter, T. D. Iminosugar inhibitors for substrate reduction therapy for the lysosomal glycosphingolipidoses in Iminosugars: From Synthesis to Therapeutic Applications (eds. Compain, P. & Martin, O.R.) 249-268 (John Wiley & Sons, West Sussex, (2007)).
13. Look, G. C., Fotsh, C. H. & Wong, C.-H. Enzyme-catalyzed organic synthesis: practical routes to aza sugars and their analogs for use as glycoprocessing inhibitors. Acc. Chem. Res. 26, 182-190 (1993).
14. Ganem, B. Inhibitors of carbohydrate-processing enzymes: design and synthesis of ugar-shaped heterocycles. Acc. Chem. Res. 29, 340-347 (1996).
15. Hoos, R., Vasella, A., Rupitz, K. & Withers, S. G. D-glyconhydroximolactams strongly nhibit α-glycosidases. Carbohydr. Res. 298, 291-298 (1997).
16. Nishimura, Y., Wang, W., Kondo, S., Aoyagi, T. & Umezawa, H. Siastatin B, a potent ialidase inhibitor: the total synthesis and absolute configuration. J. Am. Chem. Soc. 110, 7249-7250 (1988).
17. Nishimura, Y., Wang, W., Kudo, T. & Kondo, S. Total synthesis and absolute configuration of siastatin B, neuraminidase inhibitor. Bull. Chem. Soc. Jpn 65, 978-986 (1992).
18. Walker, T. E. Hogenkamp HPC. A new synthesis of L-ribofuranose derivatives. Carbohyd. Res. 32, 413-417 (1974).
19. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1-28 (1981).
20. Kudo, T., Nishimura, Y., Kondo, S. & Takeuchi, T. Totally synthetic analogues of siastatin B. I. Optically active 2-acetamidopiperidine derivatives. J. Antibiot. 45, 954-962 (1992).
21. Nishimura, Y., Kudo, T., Kondo, S. & Takeuchi, T. Totally synthetic analogues of siastatin B. II. Optically active piperidine derivatives having trifluoroacetamide and hydroxyacetamide groups at C-2. J. Antibiot. 45, 963-970 (1992).
22. Nishimura, Y. et al. Flexible synthesis and biological activity of uronic acid-type 1-Niminosugars: a new family of glycosidase inhibitors. J. Org. Chem. 65, 2-11 (2000).
23. Morgenlie, S. Synthesis of di-O-isopropylidene derivatives of L-fructose. Carbohyd. Res. 107, 137-141 (1982).
24. Nishimura, Y., Shitara, E. & Takeuchi, T. Enantioselective synthesis of a new family of α-L-fucosidase inhibitors. Tetrahedron Lett. 40, 2351-2354 (1999).
25. Shitara, E., Nishimura, Y., Kojima, F. & Takeuchi, T. Gem-diamine 1-N-iminosugars of L-fucose-type, the extremely potent L-fucosidase inhibitors. Bioorg. Med. Chem. 8, 343-352 (2000).
26. Satoh, T., Nishimura, Y., Kondo, S. & Takeuchi, T. A practical synthesis of (3S,4S,5R,6R)-4,5-dihydroxy-6-trifluoroacetamido)piperidine-3- carboxylic acid having antimetastatic activity in mice from siastatin B. Carbohydr. Res. 286, 173-178(1996).
27. Satoh, T. et al. Synthesis and antimetastatic activity of 6-trichloroacetamido and 6-guanidino analogues of siastatin B. J. Antibiot. 49, 321-325 (1996).
28. Nishimura, Y. et al. The first L-iduronic acid-type 1-N-iminosugars having inhibitory activity of experimental metastasis. J. Am. Chem. Soc. 118, 3051-3052 (1996).
29. Nishimura, Y. et al. Synthesis and antimetastatic activity of L-iduronic acid-type 1-N-iminosugars. J. Med. Chem. 40, 2626-2633 (1997).
30. Nishimura, Y., Satoh, T., Kudo, T., Kondo, S. & Takeuchi, T. Synthesis and activity of 1-N-iminosugar inhibitors, siastatin B analogues for α-N-acetylgalactosaminidase and β-N-acetylglucosaminidase. Bioorg. Med. Chem. 4, 91-96 (1996).
31. Shitara, E., Nishimura, Y., Kojima, F. & Takeuchi, T. A facile synthesis of D-galactosetype gem-diamine 1-N-iminosugr: a new family of galactosidase inhibitor. J. Antibiot. 52, 348-350 (1999). (Pubitemid 29160996)
32. Shitara, E., Nishimura, Y., Kojima, F. & Takeuchi, T. A facile synthesis of D-glucose-type gem-diamine 1-N-iminosugars: a new family of glucosidase inhibitors. Bioorg. Med. Chem. 7, 1241-1246 (1999). (Pubitemid 29281629)
33. Nishimura, Y. Glycosidase and glycosyltransferase inhibitors in Studies in Natural Products Chemistry Vol. 10 (ed. Atta-ur-Rahman), 495-583 (Elsevier, Amsterdam, (1992)).
34. Stü tz, A. D. ed. Iminosugars as Glycosidase Inhibitors: Nojirimycin and Beyond 1-412 (Wiley-VCH, New York, (1999)).
35. Martin, O. R. & Compain, P. (ed.) Iminosugars: recent insights into their bioactivity and potential as therapeutic agents. Curr. Top. Med. Chem. 3, 471-591 (2003).
36. Nishimura, Y. Gem-diamine 1-N-iminosugars and related iminosugars, candidate of therapeutic agents for tumor metastasis. Curr. Top. Med. Chem. 3, 575-591 (2003).
37. Nishimura, Y. Gem-diamine 1-N-iminosugars, a new family of glycosidase inhibitors: synthesis and biological activity. Heterocycles 67, 461-488 (2006).
38. Nishimura, Y. Iminosugar-based antitumoral agents
39. Kondo, K., Adachi, H., Shitara, E., Kojima, F. & Nishimura, Y. Glycosidase inhibitors of gem-diamine 1-N-iminosugars: Structures in media of enzyme assays. Bioorg. Med. Chem. 9, 1091-1095 (2001).
40. Lopez, O. & Bols, M. Isofagomine, noeuromycin and other 1-azasugars, iminosugarrelated glycosidase inhibitors in Iminosugars: From Synthesis to Therapeutic Applications (ed. Compain, P. & Martin, O.R.) 131-151 John Wiley & Sons, West Sussex (2007).
41. Toyoshima, M. & Nakajima, M. Human heparanase. J. Biol. Chem. 274, 24153-24160 (1999).
42. Tsuruoka, T., Tsuji, T., Nojiri, H., Holmes, H. & Hakomori, S. Selection of a mutant cell line based on differential expression of glycosphingolipid, utilizing anti-lactosylceramide antibody and complement. J. Biol. Chem. 268, 2211-2216 (1993).
43. Brown, J. R., Nishimura, Y. & Esko, J. D. Synthesis and biological evaluation of gemdiamine 1-N-iminosugars related to L-iduronic acid as inhibitors of heparan sulfate 2-O-sulfotransferase. Bioorg. Med. Chem. Lett. 16, 532-536 (2006).
44. Esko, J. D. & Lindahl, U. Molecular diversity of heparan sulfate. J. Clin. Invest. 108, 169-173 (2001).
45. Ohkawa, T. et al. Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab. Invest. 84, 1289-1304 (2004).
46. Nobuhisa, T. et al. Emergence of nuclear heparanase induces differentiation of human mammary cancer cells. Biochem. Biophys. Res. Commun. 331, 175-180 (2005).
47. Kobayashi, M. et al. Heparanase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage. Differentiation 74, 235-243 (2006).
48. Takahashi, H. et al. Involvement of heparanase in migration of microglial cells. Biochim. Biophys. Acta 1780, 709-715 (2008).
49. Esko, J. D. & Selleck, S. B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71, 435-471 (2002).
50. Turnbull, J., Powell, A. & Guimond, S. Heparan sulfate: decoding a dynamic mulnctional cell regulator. Trends Cell Biol. 11, 75-82 (2001).
51. Bernfield, M. et al. Function of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729-777 (1999).
52. Iozzo, R. V. Matrix proteoglycans: from molecular design to cellular function. Annu. Rev. Biochem. 67, 609-652 (1998).
53. Wight, T. N., Kinsella, M. G. & Qwarnstrom, E. E. The role of proteoglycans in cell adhesion, migration and proliferation. Curr. Opin. Cell Biol. 4, 739-810 (1992).
54. Ilan, N., Elkin, M. & Vlodavsky, I. Regulation, function and clinical significance if heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 38, 2018-2039 (2006).
55. Goldshmidt, O. et al. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc. Natl Acad. Sci. USA 99, 10031-10036 (2002).
56. Vlodavsky, I. et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5, 793-802 (1999).
57. Hulett, M. D., Freemen, C., Hamdorf, B. J., Baker, R. T., Harris, M. J. & Parish, C. R. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5, 803-809 (1999).
58. Nakajima, M., Morikawa, K., Fabra, A., Bucana, C. D. & Fidler, I. J. Influence of organ environment on extracellular matrix degradation activity and metastasis of human colon carcinoma cells. J. Natl Cancer Inst. 82, 1890-1898 (1990).
59. Woolley, D. E. Collagenolytic mechanisms in tumor cell invasion. Cancer Metastasis Rev. 3, 361-372 (1984).
60. Sloane, B. F. & Honn, K. V. Cystein proteinase and metastasis. Cancer Metastasis Rev. 3, 249-263 (1984).
61. Nishimura, Y. et al. Effect on spontaneous metastasis of mouse lung carcinoma by a trifluoroacetamide analogues of siastatin B. J. Antibiot. 47, 840-842 (1994).
62. Paulson, J. C. Interactions of animal viruses with cell surface receptors in The Receptors Vol. 2 (ed. Conn, P.M.) 131-219 (Academic Press, New York, (1985)).
63. Wiley, D. C. & Skehel, J. J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56, 365-394 (1987).
64. Weis, W. et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333, 426-431 (1988).
65. Klenk, H. D. & Rott, R. The molecular biology of influenza virus pathogenicity. Adv. Virus Res. 34, 247-281 (1988).
66. Colman, P. & Ward, C. W. Structure and diversity of influenza virus neuraminidase. Curr. Top. Microbiol. Immunol. 114, 177-255 (1985).
67. Gottschalk, A. Neuraminidase: the specific enzyme of influenza virus and Vibrio cholera. Biochem. Biophys. Acta 23, 645-646 (1957).
68. Schauer, R. Sialic acid and their role as biological masks. Trends Biochem. Sci. 10, 357-360 (1985).
69. Burmeister, W. P., Ruigrok, R. W. H. & Cusack, S. The 2.2Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11, 49-56 (1992).
70. Varghese, J. N. & Colman, P. M. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2Å resolution. J. Mol. Biol. 221, 473-486 (1991).
71. Nishimura, Y. et al. Synthesis of 3-episiastatin B analogues having anti-influenza virus activity. J Antibiot. 46, 1883-1889 (1993).
72. Aminoff, D. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem. J. 81, 384-392 (1961).
73. Schulman, J. L. & Palese, P. Susceptibility of different strains of influenza A virus to the inhibitory effect of 2-deoxy-2,3-dehydro-N- trifluoroacetylneuraminic acid (FANA). Virology 63, 98-104 (1975).
74. Winchester, B., Vellodi, A. & Young, E. The molecular basis of lysosomal storage diseases and their treatment. Biochem. Soc. Trans. 28, 150-154 (2000).
75. Schiffmann, R. & Brady, R. O. New prospect for the treatment of lysosomal storage diseases. Drugs 62, 733-742 (2002).
76. Ellinwood, N. M., Vite, C. H. & Haskins, M. E. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J. Gene. Med. 6, 481-506 (2004).
77. Eto, Y., Shen, J. S., Meng, X. L. & Ohashi, T. Treatment of lysosomal storage disorders: cell therapy and gene therapy. J. Inherit. Metab. Dis. 27, 411-415 (2004).
78. Butters, T. D., Raymond, D. A. & Platt, F. M. Inhibition of glycosphingolipid: application to lysosomal storage disorder. Chem. Rev. 100, 4683-4969 (2000).
79. Platt, F. M. et al. Inhibition of substrate synthesis as a strategy for glycolipids lysosomal storage disease therapy. J. Inherit. Metab. Dis. 24, 275-290 (2001).
80. Cox, T. et al. Novel oral treatment of Gaucher's disease with N-butyldeoaxynojirimycin (OGT918) to decrease substrate biosynthesis. Lancet 355, 1481-1485 (2000).
81. Wraith, J. E. et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendation for treatment in the era of enzyme replacement therapy. Eur. J. Pediatr. 167, 267-277 (2008).
82. Hunter, C. A. A rare disease in two brothers. Proc. R. Soc. Med. 10, 104-116 (1917).
83. Wilson, P. J. et al. Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc. Natl Acad. Sci. USA 87, 8531-8535 (1990).
84. Sawkar, A. R. et al. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl Acad. Sci. USA 99, 1528-15433 (2002).
85. Matsuda, J. et al. Chemical chaperon therapy for brain pathology in G(M1)-gangliosidosis. Proc. Natl Acad. Sci. USA 100, 15912-15917 (2003).
86. Perlmuntter, D. H. Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr. Res. 52, 832-836 (2002).
87. Suzuki, Y., Ogawa, S. & Sakakibara, Y. Chaperone therapy for neuronopathic lysosomal disease: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspectives in Medicinal Chemistry 3, 7-19 (2009).
88. Fan, J. Q. Iminosugars as active-site-specific chaperones for the treatment of lysosomal storage disorders in Iminosugars: From Synthesis to Therapeutic Applications (eds. Compain, P. & Martin, O.R.) 225-247 (John Wiley & Sons, West Sussex, (2007)).